XLON
FDBK
Market cap4mUSD
Dec 05, Last price
7.85GBP
1D
0.00%
1Q
-40.75%
Jan 2017
-98.14%
Name
Feedback PLC
Chart & Performance
P/E
—
P/S
2.91
EPS
—
Div Yield, %
—
Shrs. gr., 5y
51.05%
Rev. gr., 5y
15.98%
Revenues
1m
+15.27%
Net income
-3m
L+13.03%
CFO
-2m
L+22.08%
Dividend
Jul 10, 19950.4959 GBP/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in radiological images, assists research into all tumour types, and uncovers biomarkers in medical images; and TexRAD Lung, a software tool for the analysis of lung cancer for clinical use in the European Union. The company also offers Cadran image platform that provides hospitals and research institutes with a comprehensive picture archiving communication system for medical images, as well as equips users with a platform for image handling from all imaging modalities, such as CT and PET scanners; and Bleepa, a secure clinical communications platform that facilitates the sharing of clinical-grade medical images. Feedback plc was incorporated in 1958 and is headquartered in London, the United Kingdom.
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑05 | 2023‑05 | 2022‑05 | 2021‑05 | 2020‑05 | 2019‑05 | 2018‑05 | 2017‑05 | 2016‑05 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||